Press Releases

Press Releases

Year
News

23 January, 2020

Incyte to Report Fourth Quarter and Year-End Financial Results

13 January, 2020

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

07 January, 2020

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma

02 January, 2020

Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease

For Media Inquiries

Catalina Loveman Executive Director, Public Affairs

+1 302.498.6171 | media@incyte.com


For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Social Responsibility

Phone: 302.498.5914

Email: mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141

Email: layala@incyte.com

Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773

Email: cchiou@incyte.com